Kadir Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kadir Demir has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Sabahattin Kaymakoglu
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
20 shared publications - Filiz Akyüz
Department of Gastroenterology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye
19 shared publications Fatih Besisik
A Department of Gastroenterohepatology , Istanbul University, Istanbul Faculty of Medicine , Istanbul , Turkey
18 shared publicationsAtilla Okten
12 shared publications- Cetin Karaca
Department of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey
11 shared publications Sadakat Ozdil
10 shared publications
Latest Publications
- 23 March 2016
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 128 (4) , 432-438
Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study
Objectives: Interferon (IFN) therapy is associated with low rates of treatment success and high rates of recurrence in hepatitis D virus (HDV) infection. Several strategies to increase efficacy, including extending the treatment duration, have been tested. This study aimed to compare treatment outcomes between patients receiving 12 months vs. longer courses of interferon therapy for chronic delta hepatitis (CDH). Methods: Data from CDH patients receiving standard or pegylated IFN therapy were retrospectively evaluated. Patients were divided into two groups: group I received ≤12 months of therapy and group II received >12 months (maximum: 24 months) of therapy. Viral response at the end of treatment (EOT-VR), post-treatment week 24 viral response (PTW24- VR) and viral response after long-term follow-up (LTFU-VR) were compared. Parameters affecting virologic response were investigated. Results: Sixty-five patients, 14 in group I and 51 in group II, were included. The EOT-VRs were 21% and 45% (p > 0.05), and the PTW24-VRs were 7% and 41% (p = 0.02), respectively. Recurrence rates were 66% and 17% in Groups I and II, respectively. The LTFU-VRs were 7% and 37%, respectively (p = 0.04). The HDV RNA at week 24 of treatment was the only parameter significantly affecting the PTW24-VR (odds ratio: 71.2; 95% CI: 3.7–1353, p = 0.005). PTW24-VR was achieved in 68% and 5% of patients with negative and positive HDV RNA, respectively, at week 24 of treatment (p < 0.01). Conclusion: IFN treatment for up to 24 months may increase the virologic response rate for CDH. HDV RNA negativity at week 24 of treatment was a significant predictor of virologic response.
- 23 March 2016
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 128 (4) , 432-438
Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study
Objectives: Interferon (IFN) therapy is associated with low rates of treatment success and high rates of recurrence in hepatitis D virus (HDV) infection. Several strategies to increase efficacy, including extending the treatment duration, have been tested. This study aimed to compare treatment outcomes between patients receiving 12 months vs. longer courses of interferon therapy for chronic delta hepatitis (CDH). Methods: Data from CDH patients receiving standard or pegylated IFN therapy were retrospectively evaluated. Patients were divided into two groups: group I received ≤12 months of therapy and group II received >12 months (maximum: 24 months) of therapy. Viral response at the end of treatment (EOT-VR), post-treatment week 24 viral response (PTW24- VR) and viral response after long-term follow-up (LTFU-VR) were compared. Parameters affecting virologic response were investigated. Results: Sixty-five patients, 14 in group I and 51 in group II, were included. The EOT-VRs were 21% and 45% (p > 0.05), and the PTW24-VRs were 7% and 41% (p = 0.02), respectively. Recurrence rates were 66% and 17% in Groups I and II, respectively. The LTFU-VRs were 7% and 37%, respectively (p = 0.04). The HDV RNA at week 24 of treatment was the only parameter significantly affecting the PTW24-VR (odds ratio: 71.2; 95% CI: 3.7–1353, p = 0.005). PTW24-VR was achieved in 68% and 5% of patients with negative and positive HDV RNA, respectively, at week 24 of treatment (p < 0.01). Conclusion: IFN treatment for up to 24 months may increase the virologic response rate for CDH. HDV RNA negativity at week 24 of treatment was a significant predictor of virologic response.
- 17 April 2015
- Published by Wiley in Liver International
- Vol. 35 (10) , 2265-2274
Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF-R) and suboptimal response to adefovir (ADF-S).Nucleos(t)ide analogue (NA)-naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3-month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA < 20 IU/ml). CVR rates were calculated by Kaplan-Meier analysis, and a multivariate Cox proportional hazard model was generated to find out factors independently associated with CVR.A total of 165 patients (118 men, mean age 42 ± 12, 64 HBeAg(+) ) were included in the study. There were 105 patients in NA-naïve, 32 patients in ADF-S and 28 patients in ADF-R groups. All patients in the ADF-R group had multidrug resistance patterns. Mean duration of tenofovir treatment was 29 ± 14 months. CVR rates in NA-naïve, ADF-S and ADF-R groups were 65% vs. 75% vs. 58% at 12th month, 77% vs. 87% vs. 79% at 24th month and 83% vs. 94% vs. 79% at 36th month respectively. According to multivariate Cox regression model, HBeAg positivity (HR = 0.56, 95%CI 0.36-0.86, P = 0.008), high baseline HBVDNA level (HR = 0.64, 95%CI 0.55-0.74, P < 0.001) and ADF-R (HR = 0.47, 95%CI 0.28-0.81, P = 0.006) were independent predictors for CVR. Seven patients encountered mild renal dysfunction and were managed by dose adjustments.CVR rates during the follow-up show that tenofovir has a decreased, yet still potent in vivo efficacy against multidrug-resistant strains of HBV.
- 17 April 2015
- Published by Wiley in Liver International
- Vol. 35 (10) , 2265-2274
Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF-R) and suboptimal response to adefovir (ADF-S).Nucleos(t)ide analogue (NA)-naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3-month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA < 20 IU/ml). CVR rates were calculated by Kaplan-Meier analysis, and a multivariate Cox proportional hazard model was generated to find out factors independently associated with CVR.A total of 165 patients (118 men, mean age 42 ± 12, 64 HBeAg(+) ) were included in the study. There were 105 patients in NA-naïve, 32 patients in ADF-S and 28 patients in ADF-R groups. All patients in the ADF-R group had multidrug resistance patterns. Mean duration of tenofovir treatment was 29 ± 14 months. CVR rates in NA-naïve, ADF-S and ADF-R groups were 65% vs. 75% vs. 58% at 12th month, 77% vs. 87% vs. 79% at 24th month and 83% vs. 94% vs. 79% at 36th month respectively. According to multivariate Cox regression model, HBeAg positivity (HR = 0.56, 95%CI 0.36-0.86, P = 0.008), high baseline HBVDNA level (HR = 0.64, 95%CI 0.55-0.74, P < 0.001) and ADF-R (HR = 0.47, 95%CI 0.28-0.81, P = 0.006) were independent predictors for CVR. Seven patients encountered mild renal dysfunction and were managed by dose adjustments.CVR rates during the follow-up show that tenofovir has a decreased, yet still potent in vivo efficacy against multidrug-resistant strains of HBV.
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB403-AB404
Mo1350 The Evaluation of the Cyanoacrylate Injection Treatment of Gastric Varices With Endosonography
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB403-AB404
Mo1350 The Evaluation of the Cyanoacrylate Injection Treatment of Gastric Varices With Endosonography
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1157 Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Su1157 Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1013 IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Sa1013 IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB136
365 Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB136
365 Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions
- 1 December 2011
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- Vol. 19 (3)
Endosonografi ile tanı konulan ektopik pankreas: Olgu sunumu
Midede ektopik pankreas çok sık görülen bir durum olmayıp diğer submukozal lezyonlarla karışmaktadır. Ayırıcı tanıda histopatoloji yanında endosonografiden yararlanılabilir. Dispeptik yakınmalarla müracaat eden, gastroskopisinde submukozal lezyon saptanarak, endosonografi ile tanısı konulan, 28 yaşında kadın, ektopik pankreas olgusu sunulmuştur.
- 1 December 2011
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- Vol. 19 (3)
Endosonografi ile tanı konulan ektopik pankreas: Olgu sunumu
Midede ektopik pankreas çok sık görülen bir durum olmayıp diğer submukozal lezyonlarla karışmaktadır. Ayırıcı tanıda histopatoloji yanında endosonografiden yararlanılabilir. Dispeptik yakınmalarla müracaat eden, gastroskopisinde submukozal lezyon saptanarak, endosonografi ile tanısı konulan, 28 yaşında kadın, ektopik pankreas olgusu sunulmuştur.
- 13 August 2011
- Vol. 58, 900-3
Anticoagulant therapy and Budd-Chiari syndrome: is it successful?
Anticoagulant therapy is an accepted treatment for Budd-Chiari syndrome (BCS). However, the natural course of untreated patients is unclear. We aimed to evaluate the efficacy of anticoagulant therapy on survival in BCS. Between 1995 and 2007, 45 patients diagnosed with BCS based on the clinical, biochemical, radiological and histological findings were retrospectively evaluated with respect to underlying disease, therapeutic interventions, complications and overall outcome. Complications and survival during the follow-up period were compared in between anticoagulant treated and untreated cases. Mean patient age was 34.4 +/- 11.8 years and 46.7% (21) of them were male. Median followup time was 24 months (6-132); 8.9% of patients were diagnosed as acute, 31.1% as subacute and 60% as chronic BCS according to disease duration. Centrilobular necrosis was found in 16 of 36 biopsy performed patients. Etiological factors were detected in 60% of patients and 40% of them were cryptogenic. Twenty four of them received anticoagulant therapy, the remaining 21 were followed-up with supportive medical therapy. Five patients who had shunt operation were excluded for survival analyses. Complications were similar between treated and untreated cases (p>0.05). There was a positive correlation between survival and centrilobular necrosis (r=0.376, p=0.037). The mean survival periods were 95.5 months (%95 CI 73-117 months) and 72.5 months (%95 CI 42-103 months) in anticoagulant treated and untreated patients, respectively (p>0.246). Most patients with BCS are admitted to hospital at the chronic stage and more than half of them have underlying thrombotic risk factor. In our study, no beneficial effects of anticoagulant therapy were observed on the survival and complications of liver disease.
- 13 August 2011
- Vol. 58, 900-3
Anticoagulant therapy and Budd-Chiari syndrome: is it successful?
Anticoagulant therapy is an accepted treatment for Budd-Chiari syndrome (BCS). However, the natural course of untreated patients is unclear. We aimed to evaluate the efficacy of anticoagulant therapy on survival in BCS. Between 1995 and 2007, 45 patients diagnosed with BCS based on the clinical, biochemical, radiological and histological findings were retrospectively evaluated with respect to underlying disease, therapeutic interventions, complications and overall outcome. Complications and survival during the follow-up period were compared in between anticoagulant treated and untreated cases. Mean patient age was 34.4 +/- 11.8 years and 46.7% (21) of them were male. Median followup time was 24 months (6-132); 8.9% of patients were diagnosed as acute, 31.1% as subacute and 60% as chronic BCS according to disease duration. Centrilobular necrosis was found in 16 of 36 biopsy performed patients. Etiological factors were detected in 60% of patients and 40% of them were cryptogenic. Twenty four of them received anticoagulant therapy, the remaining 21 were followed-up with supportive medical therapy. Five patients who had shunt operation were excluded for survival analyses. Complications were similar between treated and untreated cases (p>0.05). There was a positive correlation between survival and centrilobular necrosis (r=0.376, p=0.037). The mean survival periods were 95.5 months (%95 CI 73-117 months) and 72.5 months (%95 CI 42-103 months) in anticoagulant treated and untreated patients, respectively (p>0.246). Most patients with BCS are admitted to hospital at the chronic stage and more than half of them have underlying thrombotic risk factor. In our study, no beneficial effects of anticoagulant therapy were observed on the survival and complications of liver disease.
- 1 October 2009
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 69 (6) , 696-702
A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease
- 1 October 2009
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 69 (6) , 696-702
A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease